Palvella Therapeutics, Inc. (PVLA) stock
Close on Nov 12, 2026Market cap $2.21BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.21B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 11.15
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$74.99M
- EPS, diluted
- -$5.49
- Book value per share
- $13.62
- Diluted shares
- 15M
Trading
- Next earnings
- Mar 30, 2027 (estimated, before the open)
- Previous close
- $163.94
- Open
- $164.16
- Day's range
- $152.13 – $165.16
- Volume
- 282,768
- Average volume (20 days)
- 281,191
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 0.65
- 52-week range
- $72.22 – $179.95
- RSI (14 days)
- 53.1
- Volatility (1 year)
- 84.4%
- Relative volume
- 1.24×
- WACC
- 8.2%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PVLA | S&P 500 | Difference | PVLA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +14.0% | -2.7% | +16.7 pts | ||
| 3 months | -1.2% | -1.7% | +0.5 pts | ||
| Year to date | +46.3% | +11.9% | +34.5 pts | ||
| 1 year | +87.9% | +12.0% | +75.9 pts | ||
| 3 years | +692.2% | +78.2% | +614.0 pts | +99.3% | +21.2% |
| 5 years | -51.5% | +73.2% | −124.8 pts | -13.5% | +11.6% |
| 10 years | +26.6% | +309.6% | −283.0 pts | +2.4% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Palvella Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- News
About Palvella Therapeutics
Pharmaceutical Preparations
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapies for individuals suffering from serious, rare skin diseases and vascular malformations that lack approved treatments. The company utilizes its proprietary QTORIN drug development platform to produce topical therapies designed to penetrate deep skin layers. Its lead product candidate is QTORIN rapamycin, an anhydrous gel in clinical development for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Additionally, the company develops QTORIN pitavastatin to treat disseminated superficial actinic porokeratosis. Its target patient populations include individuals diagnosed with these rare dermatologic and vascular conditions.
Company profile, executives and historyPalvella Therapeutics stock: common questions
What is Palvella Therapeutics's stock price?
PVLA closed at $153.18 on Nov 12, 2026, down 6.56% on the day. Over the past 52 weeks it traded between $72.22 and $179.95.
What is Palvella Therapeutics's market cap?
Palvella Therapeutics was worth $2.21B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PVLA's P/E ratio?
Palvella Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$5.49), so it has no meaningful P/E ratio.
Does Palvella Therapeutics pay a dividend?
No. Palvella Therapeutics has not paid a cash dividend over the last twelve months.
When does Palvella Therapeutics report earnings next?
Palvella Therapeutics is expected to report Q4 FY2026 results on Mar 30, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PVLA stock performed over the past year?
Including dividends, PVLA returned +87.9% over the past year, against +12.0% for the S&P 500.
How many PVLA shares are sold short?
3M shares were sold short at the latest FINRA report, 20.90% of the float, or 11.5 days of average trading volume.
Who are Palvella Therapeutics's competitors?
Companies most similar to Palvella Therapeutics by business, industry and size include QNRX, LIPO, SLGL, VRCA, HIND.
See a number that looks wrong?